Press release
Metastatic Pancreatic Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
Stay ahead with the latest insights! Download DelveInsight's comprehensive Metastatic Pancreatic Cancer Pipeline Report to explore emerging therapies, key Metastatic Pancreatic Cancer Companies, and future Metastatic Pancreatic Cancer treatment landscapes @ Metastatic Pancreatic Cancer Pipeline Outlook Report [https://www.delveinsight.com/sample-request/metastatic-pancreatic-cancer-mpc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Metastatic Pancreatic Cancer Pipeline Report
* In February 2025:- Erasca Inc.:- This is a Phase 1b/2, open-label, multicenter clinical study evaluating ERAS-007 in combination with other cancer therapies in study participants with GI malignancies. This study will serve as a platform study, allowing for evaluation of safety/tolerability and efficacy of ERAS-007 in combination with other cancer therapies. The study will initially commence with dose escalation of ERAS-007 administered in combination with encorafenib and cetuximab in study participants with metastatic colorectal cancer (CRC) harboring B-Raf proto-oncogene, serine/threonine kinase (BRAF) V600E mutation; and dose escalation of ERAS-007 administered in combination with palbociclib in study participants with metastatic CRC harboring Kirsten rat sarcoma (KRAS) or neuroblastoma rat sarcoma (NRAS) mutations and metastatic pancreatic adenocarcinoma with (PDAC) KRAS mutation.
* In January 2025:- Shanghai Yizhong Pharmaceutical Co., Ltd.- This trial is a multi-center, randomized, open, parallel-group and positive-controlled phase III trial to evaluate the efficacy and safety of paclitaxel polymeric micelles for injection plus gemcitabine as first-line treatment of metastatic pancreatic cancer compared with nab-Paclitaxel plus gemcitabine.
* In January 2025: - Verastem Inc.:- This study will assess the safety and efficacy of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel in patients with Pancreatic Ductal Adenocarcinoma (PDAC) who have been previously untreated.
* DelveInsight's Metastatic Pancreatic Cancer pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Metastatic Pancreatic Cancer treatment.
* The leading Metastatic Pancreatic Cancer Companies such as Xencor, MEI Pharma, Celldex Therapeutics, TG Therapeutics, Shanghai Unicar-Therapy Bio-medicine Technology, Chia Tai Tianqing Pharmaceutical Group, Mustang Bio, Novartis, Loxo Oncology, Genmab, Nkarta, Nurix Therapeutics, Prelude Therapeutics and others.
* Promising Metastatic Pancreatic Cancer Therapies such as Parvovirus H-1 (H-1PV), Sunitinib, Napabucasin, Nab-paclitaxel, Gemcitabine, Dasatinib, mFOLFOX6 , and others.
Discover how the Metastatic Pancreatic Cancer treatment paradigm is evolving. Access DelveInsight's in-depth Metastatic Pancreatic Cancer Pipeline Analysis for a closer look at promising breakthroughs @ Metastatic Pancreatic Cancer Clinical Trials and Studies [https://www.delveinsight.com/sample-request/metastatic-pancreatic-cancer-mpc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Metastatic Pancreatic Cancer Emerging Drugs Profile
* Motixafortide: BioLineRx
Motixafortide (formerly known as BL-8040/BKT140) is a novel selective inhibitor of the CXCR4 chemokine receptor. CXCR4, is a well validated therapeutic target that is involved in the mobilization and trafficking of hematopoietic stem cells, immune cells and cancer cells from the bone marrow and the lymph nodes to the peripheral blood. Motixafortide is being developed as a platform for several indications including mobilization of hematopoietic stem cells (HSCs) for autologous transplantations, treatment of solid tumors, and other hematological malignancies.
* Fuzuloparib: Jiangsu Hengrui Pharmaceuticals
Fuzuloparib is a small molecule, orally active PARP inhibitor being developed by Jiangsu Hengrui Pharmaceuticals Co for the treatment of solid cancers. Fuzuloparib has been approved in China for the treatment of ovarian cancer (including fallopian tube cancer or primary peritoneal cancer), and phase II and III trials are investigating fuzuloparib for the treatment of other solid cancers, including cancers of the pancreas, breast, prostate and lungs.
* HP518: Hinova Pharmaceuticals
HP518, a highly selective and orally bioavailable chimeric degrader targeting androgen receptor (AR) with the potential to overcome the drug resistance of prostate cancer due to some specific AR mutations. In discovery and preclinical studies, HP518 showed high degradation activity against wild type AR and some specific AR mutants that are resistant to enzalutamide, and excellent antitumor activity in xenograft mouse models. HP518 is highly selective for AR.
The Metastatic Pancreatic Cancer pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Pancreatic Cancer with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Pancreatic Cancer Treatment.
* Metastatic Pancreatic Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Metastatic Pancreatic Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Pancreatic Cancer market.
Get a detailed analysis of the latest innovations in the Metastatic Pancreatic Cancer pipeline. Explore DelveInsight's expert-driven report today! @ Metastatic Pancreatic Cancer Unmet Needs [https://www.delveinsight.com/sample-request/metastatic-pancreatic-cancer-mpc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Metastatic Pancreatic Cancer Companies
Xencor, MEI Pharma, Celldex Therapeutics, TG Therapeutics, Shanghai Unicar-Therapy Bio-medicine Technology, Chia Tai Tianqing Pharmaceutical Group, Mustang Bio, Novartis, Loxo Oncology, Genmab, Nkarta, Nurix Therapeutics, Prelude Therapeutics and others.
Metastatic Pancreatic Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
Metastatic Pancreatic Cancer Products have been categorized under various Molecule types such as
* Small molecule
* Cell Therapy
* Peptides
* Polymer
* Small molecule
* Gene therapy
Download DelveInsight's latest report to gain strategic insights into upcoming Metastatic Pancreatic Cancer Therapies and key Metastatic Pancreatic Cancer Developments @ Metastatic Pancreatic Cancer Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/metastatic-pancreatic-cancer-mpc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Metastatic Pancreatic Cancer Pipeline Report
* Coverage- Global
* Metastatic Pancreatic Cancer Companies- Xencor, MEI Pharma, Celldex Therapeutics, TG Therapeutics, Shanghai Unicar-Therapy Bio-medicine Technology, Chia Tai Tianqing Pharmaceutical Group, Mustang Bio, Novartis, Loxo Oncology, Genmab, Nkarta, Nurix Therapeutics, Prelude Therapeutics and others.
* Promising Metastatic Pancreatic Cancer Therapies - Parvovirus H-1 (H-1PV), Sunitinib, Napabucasin, Nab-paclitaxel, Gemcitabine, Dasatinib, mFOLFOX6 , and others.
* Metastatic Pancreatic Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Metastatic Pancreatic Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Metastatic Pancreatic Cancer drug development? Find out in DelveInsight's exclusive Metastatic Pancreatic Cancer Pipeline Report-access it now! @ Metastatic Pancreatic Cancer Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/metastatic-pancreatic-cancer-mpc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Metastatic Pancreatic Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Metastatic Pancreatic Cancer- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Rucaparib: Eleison Pharmaceuticals
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* MDB 401 B: Panbela Therapeutics
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* SBP 101: Takeda Oncology
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Metastatic Pancreatic Cancer Key Companies
* Metastatic Pancreatic Cancer Key Products
* Metastatic Pancreatic Cancer- Unmet Needs
* Metastatic Pancreatic Cancer- Market Drivers and Barriers
* Metastatic Pancreatic Cancer- Future Perspectives and Conclusion
* Metastatic Pancreatic Cancer Analyst Views
* Metastatic Pancreatic Cancer Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=metastatic-pancreatic-cancer-clinical-trials-and-studies-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/cart-cell-therapy-competitive-landscape
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Metastatic Pancreatic Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies here
News-ID: 3872510 • Views: …
More Releases from ABNewswire
Rhino Rescue's Quality Pledge: Unveiling the Extreme Resilience of Core Componen …
Discover Rhino Rescue's quality pledge through our extreme component testing. See why our tactical gear is built to perform.
Our Commitment and Responsibility
In the life and death arena of emergency response, where seconds matter, the dependability of your equipment is absolute. It is a fact that has been guiding our mission since our parent company, Nanchi Medical, was established in 2010. Having a 14-year history in the first aid industry and…
Tampa SEO Launches Cutting-Edge Local Search Optimization Services to Help Tampa …
Tampa SEO, a full-service digital marketing agency based in Tampa Bay, today announced the official launch of its enhanced SEO and digital marketing services at http://tampa-seo.net. The company specializes in helping local businesses increase their online visibility, generate qualified leads, and outperform competitors through data-driven, ethical search engine optimization strategies.
Helping Local Businesses Thrive in the Digital Age
With nearly 97% of consumers searching online for local services before making a purchase,…
Fibromyalgia Market Expected to Gain Momentum Through 2034, According to DelveIn …
The Key Fibromyalgia Companies in the market include - Tonix Pharmaceutical, UCB Biopharma SRL, GlaxoSmithKline, UCB Pharma, Pierre Fabre Medicament, UCB Pharma, Eli Lilly and Company, Merck, Aptinyx, Astellas Pharma, AstraZeneca, RiboCor, Inc., Bial - Portela C S.A, and others.
DelveInsight's "Fibromyalgia Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Fibromyalgia, historical and forecasted epidemiology as well as the Fibromyalgia market trends in the United States,…
DMB Plumbing & Heating Urges Homeowners to Schedule Pre-Winter Heating Inspectio …
DMB Plumbing & Heating Inc. of Bridgewater, led by Dean Blanchard, is urging homeowners to schedule pre-winter heating inspections.
As temperatures in Massachusetts begin to dip and residents prepare their homes for another New England winter, DMB Plumbing & Heating Inc., a locally owned and operated company based in Bridgewater, is reminding homeowners of the importance of pre-winter heating inspections.
Founded and operated by Dean Blanchard, DMB Plumbing & Heating has long…
More Releases for Pancreatic
Growing Pancreatic Cancer Cases : Pivotal Factor Influencing Pancreatic Cancer D …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Pancreatic Cancer Drugs Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for pancreatic cancer drugs has seen consistent growth over the past few years. An escalation from $3.96 billion in 2024 to $4.1 billion in 2025 is projected, marking a compound annual…
Pancreatic Cancer Diagnostic Market Surges In Response To Escalating Prevalence …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Pancreatic Cancer Diagnostic Market Through 2025?
The market size for pancreatic cancer diagnostics has been witnessing robust growth in recent times. There will be a growth from $4.24 billion in 2024 to $4.55 billion in 2025, showcasing a Compound Annual Growth Rate…
Pancreatic Cancer Diagnostic Market Surges In Response To Escalating Prevalence …
The Pancreatic Cancer Diagnostic Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Pancreatic Cancer Diagnostic Market Size and Projected Growth Rate?
There has been a significant expansion in the pancreatic cancer diagnostic market recently. This market is projected to increase from a value…
Pancreatic Amylase Reagent Kits: Streamlining Enzyme Analysis for Efficient Panc …
Pancreatic Amylase Reagent Kits Market 2023 Forecast: Unveiling Opportunities and Growth
Pancreatic Amylase Reagent Kits Market research report helps to recognize the market challenges and opportunities. Global Pancreatic Amylase Reagent Kits Market report contains the recent forecast research for the predicted period. The report extensively offers the latest information about the technological developments and market growth prospect on the basis of the regional landscape. This Report offers a complete evaluation of…
Pancreatic Cancer Therapy Market: Rise in Number of Patients Suffering with Panc …
Pancreatic cancer is one of the aggressive cancers that originate in the tissues of the pancreas and rapidly spreads to the nearby organs. Pancreatic cancer is the 12th most commonly occurring cancer in the world. According to the American Cancer Society, ~55,440 patients in the US are expected to be diagnosed with pancreatic cancer in 2018. Moreover, the ACS also reports that pancreatic cancer is the third leading cause of…
Pancreatic Cancer Treatment
Pancreatic Cancer Treatment Market describes its growth, size, share, Forecast and trends to 2025
Pancreatic Cancer Treatment Market Production and Demand Analysis 2019 to 2025
Pancreatic Cancer Treatment Market 2019 Manufacturing Analysis and Development Forecast 2025
Pancreatic Cancer Treatment Market 2019: Recent Study Including Growth Factors, Regional Drivers, Forecast 2025
Pancreatic Market to Insight By 2025: Top Key Vendors
Pancreatic cancer arises when cells in the pancreas, a glandular organ behind the stomach, begin to…
